Akums Drugs and Pharmaceuticals Limited (IN:AKUMS)
:AKUMS
Want to see IN:AKUMS full AI Analyst Report?
Top Page
Akums Drugs and Pharmaceuticals Limited
(AKUMS)
Select Model
Select Model
Rating:70Outperform
Price Target:
₹605.00
▲(44.01% Upside)
Action:UpgradedDate:04/17/26
The score is driven primarily by solid financial performance (improving profitability, strong cash generation, and much lower leverage) and supportive technical uptrend signals. These positives are tempered by a relatively high P/E valuation and signs of short-term technical overextension (very high Stochastic).
Positive Factors
Much lower leverage
A dramatic reduction in leverage materially lowers financial risk and interest burden, giving management durable flexibility to fund capex, pursue strategic investments, or weather cyclical downturns. For a CDMO, this enhances credibility with clients and supports long-term contract wins.
Negative Factors
Declining EBIT margin
A drop in EBIT margin signals operating-pressure at the core business level, which may reflect rising overheads, cost of goods, or margin dilution from new lower-margin contracts. Persistent EBIT compression would erode operating cash flow and limit strategic reinvestment over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Much lower leverage
A dramatic reduction in leverage materially lowers financial risk and interest burden, giving management durable flexibility to fund capex, pursue strategic investments, or weather cyclical downturns. For a CDMO, this enhances credibility with clients and supports long-term contract wins.
Read all positive factors
Akums Drugs and Pharmaceuticals Limited (AKUMS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹80.96B
Dividend YieldN/A
Average Volume (3M)11.50K
Price to Earnings (P/E)26.2
Beta (1Y)1.27
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees7,536
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.33
Shares Outstanding157,393,980
10 Day Avg. Volume12,021
30 Day Avg. Volume11,497
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.32
Price to Sales (P/S)1.74
P/FCF Ratio36.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹680.00Price Target Upside61.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)24.77
Revenue Forecast (FY)₹48.77B
Akums Drugs and Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary su...
How the Company Makes Money
AKUMS makes money mainly by providing contract manufacturing and related development services to pharmaceutical and healthcare companies that market products under their own brands. Its core revenue stream is manufacturing fees embedded in the sal...
Akums Drugs and Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
65
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.26B | 40.71B | 40.20B | 34.75B | 36.47B |
| Gross Profit | 7.62B | 16.05B | 14.37B | 11.67B | 12.69B |
| EBITDA | 2.39B | 5.29B | 1.31B | 3.09B | -821.80M |
| Net Income | 1.88B | 3.38B | -40.35M | 948.55M | -2.53B |
Balance Sheet | |||||
| Total Assets | 51.59B | 41.13B | 35.16B | 32.67B | 30.69B |
| Cash, Cash Equivalents and Short-Term Investments | 16.78B | 5.82B | 2.88B | 1.50B | 1.03B |
| Total Debt | 902.87M | 882.12M | 5.65B | 6.19B | 3.95B |
| Total Liabilities | 19.91B | 10.50B | 27.96B | 25.43B | 24.44B |
| Stockholders Equity | 31.49B | 30.47B | 7.09B | 7.17B | 6.22B |
Cash Flow | |||||
| Free Cash Flow | 13.13B | 1.93B | 1.87B | -1.52B | -2.26B |
| Operating Cash Flow | 15.47B | 4.65B | 4.98B | 1.77B | 318.54M |
| Investing Cash Flow | -12.71B | -5.48B | -3.30B | -3.05B | -2.35B |
| Financing Cash Flow | -5.29B | 727.88M | -1.08B | 1.25B | 2.36B |
Akums Drugs and Pharmaceuticals Limited Technical Analysis
Positive
420.10
Price Trends
482.81
Positive
457.72
Positive
473.76
Positive
Market Momentum
16.91
Negative
64.85
Neutral
88.30
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AKUMS, the sentiment is Positive. The current price of 420.1 is below the 20-day moving average (MA) of 496.92, below the 50-day MA of 482.81, and below the 200-day MA of 473.76, indicating a bullish trend. The MACD of 16.91 indicates Negative momentum. The RSI at 64.85 is Neutral, neither overbought nor oversold. The STOCH value of 88.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:AKUMS.
Akums Drugs and Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹80.96B | 26.19 | ― | ― | ― | ― | |
66 Neutral | ₹3.29B | 48.53 | ― | ― | -0.51% | 124.85% | |
64 Neutral | ₹37.19B | 25.06 | ― | 0.96% | 8.53% | 21.02% | |
64 Neutral | ₹7.51B | 19.44 | ― | 1.96% | -3.66% | -65.22% | |
64 Neutral | ₹9.08B | 12.53 | ― | ― | 16.37% | 44.86% | |
58 Neutral | ₹1.21B | 16.40 | ― | 1.62% | -2.02% | 29.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:AKUMS
Akums Drugs and Pharmaceuticals Limited
531.60
5.60
1.06%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
141.00
62.00
78.48%
IN:BALPHARMA
Bal Pharma Limited
75.77
-25.92
-25.49%
IN:INDRAMEDCO
Indraprastha Medical Corporation Limited
414.40
15.37
3.85%
IN:KOPRAN
Kopran Limited
159.95
-32.85
-17.04%
IN:WANBURY
Wanbury Limited
260.30
15.45
6.31%
Akums Drugs and Pharmaceuticals Limited Corporate Events
ICRA Reaffirms Akums Ratings and Assigns Top Grade to New Commercial Paper
Apr 11, 2026
Akums Drugs and Pharmaceuticals Limited has had its long- and short-term working capital limits reaffirmed at [ICRA]AA (Stable) and [ICRA]A1+, while ICRA has also assigned an [ICRA]A1+ rating to the company’s proposed commercial paper progra...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.